Skip to main content
Top
Published in: Clinical Rheumatology 2/2004

01-04-2004 | Letter

CTLA-4 gene polymorphism in promoter and exon-1 regions is not associated with Chinese patients with rheumatoid arthritis

Authors: Ming-Fei Liu, Chrong-Reen Wang, Pei-Chih Chen, Tsung-Liang Lin

Published in: Clinical Rheumatology | Issue 2/2004

Login to get access

Excerpt

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a structural homologue of CD28, but plays a negative regulatory role in T-cell response [1, 2]. CTLA-4 has been reported to be an important negative regulator of autoimmune diseases [3]. The human CTLA-4 gene is located on chromosome 2q33 and three polymorphisms have been reported to date. The first was a dinucleotide repeat polymorphism of exon 3 [4]. At least 23 different alleles ranging from 7 to 30 AT repeats have been identified. The second polymorphism was a G to A transition at position 49 of exon 1. The single nucleotide polymorphism led to an alanine to threonine amino acid substitution of codon 17 of the leader peptide [5, 6]. The third polymorphism was identified in the promoter sequence with a C to T transition at position –318 of the promoter sequence [7]. …
Literature
1.
go back to reference Harper K, Balzano C, Rouvier E, Matti MG, Luciani MF, Golstein P (1991) CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol 147:1037–1044PubMed Harper K, Balzano C, Rouvier E, Matti MG, Luciani MF, Golstein P (1991) CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol 147:1037–1044PubMed
2.
go back to reference Walunas TL, Bakker CY, Bluestone JA (1996) CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 183:2541–2550PubMed Walunas TL, Bakker CY, Bluestone JA (1996) CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 183:2541–2550PubMed
3.
go back to reference Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA (1996) CTLA-4: a negative regulator of autoimmune disease. J Exp Med 184:783–788PubMed Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA (1996) CTLA-4: a negative regulator of autoimmune disease. J Exp Med 184:783–788PubMed
4.
go back to reference Polymeropoulos MH, Xiao H, Rath DS, Merril CR (1991) Dinucleotide repeat polymorphism at the human CTLA-4 gene. Nucleic Acids Res 19:4018–4019 Polymeropoulos MH, Xiao H, Rath DS, Merril CR (1991) Dinucleotide repeat polymorphism at the human CTLA-4 gene. Nucleic Acids Res 19:4018–4019
5.
go back to reference Larsen ZM, Kristiansen OP, Mato E et al. (1999) IDDM12 (CTLA-4) on 2q33 and IDDM13 on 2q34 in genetic susceptibility to type 1 diabetes. Autoimmunity 31:35–42PubMed Larsen ZM, Kristiansen OP, Mato E et al. (1999) IDDM12 (CTLA-4) on 2q33 and IDDM13 on 2q34 in genetic susceptibility to type 1 diabetes. Autoimmunity 31:35–42PubMed
6.
go back to reference Nistico L, Buzzetti R, Pritchard LE et al. (1996) The CTLA-4 gene region of chromosome 2q33 is linked to and associated with type 1 diabetes. Hum Mol Genet 5:1075–1080PubMed Nistico L, Buzzetti R, Pritchard LE et al. (1996) The CTLA-4 gene region of chromosome 2q33 is linked to and associated with type 1 diabetes. Hum Mol Genet 5:1075–1080PubMed
7.
go back to reference Deichmann K, Heinzmann A, Bruggenolte E, Forster J, Kuehr J (1996) A Mse I RFLP in the human CTLA-4 promoter. Biochem Biophys Res Commun 225:817–818PubMed Deichmann K, Heinzmann A, Bruggenolte E, Forster J, Kuehr J (1996) A Mse I RFLP in the human CTLA-4 promoter. Biochem Biophys Res Commun 225:817–818PubMed
8.
go back to reference Kristiansen OP, Larsen ZM, Pociot F (2000) CTLA-4 in autoimmune diseases a general susceptibility gene to autoimmunity? Genes Immun 1:170–184PubMed Kristiansen OP, Larsen ZM, Pociot F (2000) CTLA-4 in autoimmune diseases a general susceptibility gene to autoimmunity? Genes Immun 1:170–184PubMed
9.
go back to reference Seidl C, Donner H, Fischer B et al. CTLA-4 codon 17 dimorphism in patients with rheumatoid arthritis. Tissue Antigens 51:62–66PubMed Seidl C, Donner H, Fischer B et al. CTLA-4 codon 17 dimorphism in patients with rheumatoid arthritis. Tissue Antigens 51:62–66PubMed
10.
go back to reference Worthington J, Barton A, Myerscough A (1997) Polymorphic CTLA-4 alleles are not associated with rheumatoid arthritis. Am J Hum Genet 61:2361–2361 Worthington J, Barton A, Myerscough A (1997) Polymorphic CTLA-4 alleles are not associated with rheumatoid arthritis. Am J Hum Genet 61:2361–2361
11.
go back to reference Barton A, Myerscough A, John S, Gonzalez-Gay M, Ollier W, Worthington J (2000) A single nucleotide polymorphism in exon 1 of cytotoxic T-lymphocyte-associated-4 (CTLA-4) is not associated with rheumatoid arthritis. Rheumatology 39:63–66CrossRefPubMed Barton A, Myerscough A, John S, Gonzalez-Gay M, Ollier W, Worthington J (2000) A single nucleotide polymorphism in exon 1 of cytotoxic T-lymphocyte-associated-4 (CTLA-4) is not associated with rheumatoid arthritis. Rheumatology 39:63–66CrossRefPubMed
12.
go back to reference Yanagawa T, Gomi K, Nakao EI, Inada S (2000) CTLA-4 gene polymorphism in Japanese patients with rheumatoid arthritis. J Rheumatol 27:2740–2742PubMed Yanagawa T, Gomi K, Nakao EI, Inada S (2000) CTLA-4 gene polymorphism in Japanese patients with rheumatoid arthritis. J Rheumatol 27:2740–2742PubMed
Metadata
Title
CTLA-4 gene polymorphism in promoter and exon-1 regions is not associated with Chinese patients with rheumatoid arthritis
Authors
Ming-Fei Liu
Chrong-Reen Wang
Pei-Chih Chen
Tsung-Liang Lin
Publication date
01-04-2004
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 2/2004
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-003-0776-4

Other articles of this Issue 2/2004

Clinical Rheumatology 2/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine